ImmunoGen, Inc.
IMGN · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $113,425 | $83,153 | $49,869 | $41,167 |
| % Growth | 36.4% | 66.7% | 21.1% | – |
| Cost of Goods Sold | $2,155 | $909 | $626 | $176 |
| Gross Profit | $111,270 | $82,244 | $49,243 | $40,991 |
| % Margin | 98.1% | 98.9% | 98.7% | 99.6% |
| R&D Expenses | $47,570 | $50,077 | $51,620 | $58,485 |
| G&A Expenses | $0 | $36,356 | $0 | $23,793 |
| SG&A Expenses | $37,744 | $36,356 | $40,016 | $42,065 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $18,272 |
| Other Operating Expenses | -$164 | -$8 | $0 | $0 |
| Operating Expenses | $85,314 | $86,433 | $91,636 | $100,550 |
| Operating Income | $25,956 | -$4,189 | -$42,393 | -$59,559 |
| % Margin | 22.9% | -5% | -85% | -144.7% |
| Other Income/Exp. Net | $3,626 | $818 | $1,379 | $1,769 |
| Pre-Tax Income | $29,582 | -$3,371 | -$41,014 | -$57,790 |
| Tax Expense | -$1,166 | $877 | -$448 | $1,218 |
| Net Income | $30,748 | -$4,248 | -$40,566 | -$59,008 |
| % Margin | 27.1% | -5.1% | -81.3% | -143.3% |
| EPS | 0.1 | -0.016 | -0.16 | -0.23 |
| % Growth | 721.1% | 89.9% | 30.4% | – |
| EPS Diluted | 0.1 | -0.016 | -0.16 | -0.23 |
| Weighted Avg Shares Out | 273,341 | 263,446 | 258,848 | 253,263 |
| Weighted Avg Shares Out Dil | 287,590 | 263,446 | 258,848 | 254,405 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,844 | $1,905 | $2,169 | $2,158 |
| Interest Expense | $1,054 | $1,079 | $853 | $971 |
| Depreciation & Amortization | $423 | $427 | $2,232 | $2,740 |
| EBITDA | $31,059 | -$1,865 | -$37,929 | -$54,079 |
| % Margin | 27.4% | -2.2% | -76.1% | -131.4% |